The amygdala between sensation and affect: a role in pain. by Veinante, P. (Pierre) et al.
JMP
Veinante et al. Journal of Molecular Psychiatry 2013, 1:9
http://www.jmolecularpsychiatry.com/content/1/1/9REVIEW Open AccessThe amygdala between sensation and affect: a
role in pain
Pierre Veinante1,2*, Ipek Yalcin1,2 and Michel Barrot1,2Abstract
The amygdala is a structure of the temporal lobe thought to be involved in assigning emotional significance to
environmental information and triggering adapted physiological, behavioral and affective responses. A large body
of literature in animals and human implicates the amygdala in fear. Pain having a strong affective and emotional
dimension, the amygdala, especially its central nucleus (CeA), has also emerged in the last twenty years as key
element of the pain matrix. The CeA receives multiple nociceptive information from the brainstem, as well as highly
processed polymodal information from the thalamus and the cerebral cortex. It also possesses the connections that
allow influencing most of the descending pain control systems as well as higher centers involved in emotional,
affective and cognitive functions. Preclinical studies indicate that the integration of nociceptive inputs in the CeA
only marginally contributes to sensory-discriminative components of pain, but rather contributes to associated
behavior and affective responses. The CeA doesn’t have a major influence on responses to acute nociception in
basal condition, but it induces hypoalgesia during aversive situation, such as stress or fear. On the contrary, during
persistent pain states (inflammatory, visceral, neuropathic), a long-lasting functional plasticity of CeA activity
contributes to an enhancement of the pain experience, including hyperalgesia, aversive behavioral reactions and
affective anxiety-like states.
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Many cerebral structures, constituting the pain matrix,
participate in nociception and in the expression and
modulation of pain. They transmit and decode nocicep-
tive information, generate, amplify or reduce the pain
sensation, allow expression of defensive or distress be-
havior, and influence the affect. Among these brain
structures, the amygdaloid complex, or amygdala, ap-
pears as a key component of the pain matrix [1]. Indeed,
while this group of sub-cortical nuclei within the tem-
poral lobe is well known for its critical role in the con-
trol of emotions [2], it has also been the target for a
large number of fundamental research in the pain field
during the two past decades. Overall, the amygdala is
considered to provide an emotional value – either posi-
tive or negative – to sensory information, thus leading* Correspondence: veinantep@inci-cnrs.unistra.fr
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reproduction in any medium, provided the orto adapted behavioral and affective responses and con-
tributing to emotional memory. This role has been more
particularly studied in the conditioned fear experimental
paradigm [2-4]. Such conditioning is an adaptive process
in response to potential danger. As nociceptive stimula-
tions are also potentially harmful for body integrity, it is
not surprising that the amygdala can integrate various
nociceptive information to initiate or modulate the auto-
nomic and behavioral responses according to the envir-
onmental context (internal and external) and to the
affective state. This adaptation includes mechanisms of
hypoalgesia/analgesia that allows reflex inhibition and fa-
cilitates fight or flight responses. Moreover, this brain
structure participates in the anticipation/prediction of
potential danger, based on salient sensory cues (sounds,
images, odors…), to initiate the same adaptive responses
as in direct presence of the danger. This is for example
leading to conditioned or to stress-induced analgesia.
Pain includes a strong emotional component making it
aversive and a reciprocal relation exists between pain
and affective states. Stress can either inhibit or amplifyal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Anatomical organization of the amygdala. A: Frontal
section of a rat brain at the level of the amygdala processed for
acetylcholinesterase staining. The boxed area indicates the position
of the magnified region right-hand. The four main groups are
outlined: superficial (purple), basolateral (red), central (blue), medial
(green). B: Schematic representation of the main amygdala nuclei.
The basolateral group (red) includes the lateral (L), basolateral (BL),
basolateral ventral (BLV) and basomedial (BM) nuclei. The central
group is represented by the central nucleus with its capsular (CeLC),
lateral (CeL) and medial (CeM) subdivisions. The medial (green) and
superficial (purple) groups are represented at this level by the
medial (MeA) and anterior cortical (ACo) nuclei, respectively. The
intercalated cell masses (ITC, black) appear wedged between BL and
CeA. Other abbreviations: CPu: caudate-putamen; ic: internal capsule;
GP: globus pallidus; ot: optic tract. Photographs of
acetylcholinesterase staining from the authors’ archive.
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associated with more intense pain sensation, particularly
when pain becomes chronic. In such chronic pain state,
the amygdala could contribute to the hyperalgesia as
well as to the anxio-depressive consequences of pain.
A few publications reviewed the role of the amygdala
in persistent pain [5,6]. The present review will consider
the recent published data on the subject and address the
key role of amygdala, especially its central nucleus, in
various pain processes, either physiological or patho-
logical. This will be done by reminding the anatomical
context and presenting the morphological and functional
evidences allowing insertion of the amygdala within the
pain matrix. Then, we will show that the amygdala can
exert either inhibitory or facilitating action on
nociception and pain as well as on its affective compo-
nent and consequences. Finally, we will address recent
electrophysiological, neurochemical and biochemical
data that are giving insights into underlying cellular and
molecular mechanisms. While experimental data that
are presented concern studies conducted in rodents, we
will confront them with human brain imaging studies,
thus stressing the potential role of the amygdala in hu-
man pain, especially with clinical relevance.
Review
Amygdala and extended amygdala
The amygdala is a nuclear complex with almond shape,
located in the temporal lobe of mammals and identified
by Burdach at the start of 19th century. It is an hetero-
geneous structure, grouping around a dozen of nuclei
depending on the considered nomenclature, these nuclei
being classically clustered in 4 groups: superficial,
basolateral, central and medial (Figure 1) [7,8]. The first
two groups constitute the corticobasal amygdala that
shows cortical-like characteristics [8]. Its main nuclei,
the lateral and the basolateral nuclei are known as the
basolateral amygdala (BLA) and mostly contain projec-
tion neurons of pyramidal type, synthesizing glutamate.
It is reciprocally connected with the cerebral cortex, and
sends a major projection to the striatal complex, espe-
cially in its ventral part [9,10]. The BLA also densely in-
nervates the central and medial groups of amygdala
nuclei. These last two groups display an organization
that is similar to the one of the basal ganglia, with
striatopallidal-like neuronal morphology [8,11]. More-
over, the central and the medial amygdala groups receive
information from the cerebral cortex but do not send
any direct projection to it. In addition to the four
groups, a few nuclei of the amygdala remain unclassified,
among them the intercalated cell masses which are small
clusters of densely packed GABAergic neurons [12].
The central nucleus of the amygdala (CeA), main com-
ponent of the central group of amygdala nuclei, isconsidered as the output nuclei of the amygdaloid com-
plex. It integrates information treated by the corticobasal
group and it influences effector centers. The CeA is also
reciprocally connected to more rostral forebrain struc-
tures, such as the lateral part of the bed nucleus of the
stria terminalis (BSTL) and the dorsal part of the
substantia innominata. This group of interconnected
structures presents strong morphofunctional homogen-
eity and is designed as the central extended amygdala
[8,13]. In this review, we will more specifically detail data
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ture for its role in nociception and pain, and also refer to
findings on the extended amygdala, as CeA functions are
closely related to this forebrain macrostructure.
The CeA has three subdivisions: capsular (CeLC), cen-
tral (CeL) and medial (CeM), that are defined based on
cytoarchitecture, neurochemistry and connectivity [8,11].
The CeLC and the CeL mostly contain medium-size
spiny striatal-like neurons, while the CeM main neur-
onal population has a leptodendritic pallidal-like morph-
ology (i.e. neurons with long dendrites with few or no
spines). Neurons from these 3 sub-divisions co-synthesize
GABA and neuropeptides, such as opioid peptides (en-
kephalins, dynorphin, endorphins), corticotropin-releasing
factor (CRF), neurotensin, somatostatin, galanin or sub-
stance P [11,14-16]. These peptides and others, such as
calcitonin gene-related peptide (CGRP), are also present
in a dense neuropile of incoming axonal terminals [11].
Connections of the CeA (Figure 2) are characterized by
strong relation, often reciprocal, with autonomic and
modulatory centers of the hypothalamus and the brain-
stem. This includes the dorsal vagal complex, the
parabrachial nucleus, the periaqueductal gray (PAG), the
medullary and mesopontine reticular formation, the para-
ventricular nucleus of the hypothalamus and the lateral
hypothalamus [7,8,11]. The midbrain dopaminergic centers,
the locus coeruleus and the dorsal raphe are also under
CeA control, and the CeA receives monoaminergic inputs
from these structures. The connections of the CeA with the
thalamus are sparser but reciprocal, and concern the para-
ventricular, posterior intralaminar and subparafascicular
nuclei [8]. Cortical inputs mainly arise from non-isocorticalFigure 2 Main connections of the CeA involved in pain processes. The
cerebral cortex and the thalamus essentially through inputs from the latera
information from the parabrachial nucleus. Intercalated cell masses (ITC) pr
contact neurons in the capsular (CeLC) and lateral (CeL) subdivisions of the
subdivision (CeM). Efferents arise mainly from the CeM and target the othe
the integrative, modulator and effector centers in the hypothalamus and th
the central nucleus.areas (prefrontal, insular and perirhinal cortices) and from
the corticobasal nuclei of the amygdala [11,17]. While the
CeA doesn’t directly project to the cerebral cortex, it has
outputs toward substantia innominata cholinergic neurons
that are projecting to the cortex [8]. The amygdaloid inter-
calated cell masses also provide an intra-amygdaloid input
to the CeA [12]. Last, the CeA is interconnected with other
components of the central extended amygdala through a
dense network of reciprocal projections. Within the CeA,
information follow a latero-median flux [11]: most afferents
do synapses in the CeLC and the CeL, and neurons of these
two subdivisions then influence the CeM where most of
the efferent projection neurons of the CeA are found
(Figure 2). Globally, these morphofunctional character-
istics are similar to other components of the central ex-
tended amygdala [8]. This general organization of
amygdala and extended amygdala described in rodent is
similar to the human brain [8,13].
The CeA receives multiple nociceptive informations
Among the various CeA afferents, two main pathways
are preferentially conveying nociceptive information
(Figure 2). A first pathway originates from the BLA, and
conveys highly integrated polymodal information, in-
cluding nociceptive, from the thalamus and the cerebral
cortex, allowing for example fear conditioning [2,4,7]. A
cascade of projections, originating in the ventroposterior,
posterior, triangular and posterior intralaminar nuclei of
the thalamus, the second somatosensory area and the in-
sular cortex, brings nociceptive information to the BLA
which in turn transmits it to the CeA [7,17,18]. More
precisely, the lateral nucleus of the amygdala projectsCeA received highly processed polymodal information from the
l (L) and basolateral (BL) nuclei, and more direct nociceptive
ovide an inhibitory input driven by L and BL. Most of these afferents
central nucleus which control the activity of neurons in the medial
r components of the central extended amygdala, thalamic nuclei and
e brainstem. Most of these structures send a reciprocal projection to
Table 1 Reported changes in the rodent CeA in different
pain situations
Pain situationa Changes in the CeA Reference
Acute somatic
stimulations




ip acetic acid - Increased c-fos mRNA expression [24]
Esophageal
acetic acid
- Increased c-Fos immunoreactivity [25]
Colitis - Increased neuronal excitability [26,27]
- Enhanced the PB-CeA, but not the
BLA-CeA transmission
- Increased crf mRNA expression
Cystitis - Increased c-Fos and Krox-24
imunoreactivities
[28,29]









- Increased ERK activation [32]
- Enhanced the PB-CeA transmission
Knee joint
arthritis
- Increased spontaneous activity in the
right CeA
[33-36]
- Increased neuronal excitability in the
right CeA
- Enhanced the PB-CeA and the BLA-
CeA transmission
- Increased mGluR1 and mGluR5
expression





- Increased spontaneous and evoked
activity differentially in the left and
right CeA
[37-41]
- Enhanced the PB-CeA transmission
- Increased crf mRNA expression and
CRF immunoreactivity
- Increased glucocorticoid receptor
mRNA expression
- Increased cell proliferation
a Pain situation: acute somatic stimulations: nociceptive mechanical pinches or
thermal stimulations applied on different body parts; ip acetic acid:
intraperitoneal injection of acetic acid; colitis: inflammation by intracolonic
infusion TNBS (2,4,6-trinitrobenzenesulfonic acid) or zymosan; cystitis: urinary
bladder inflammation by intraperitoneal injection of cyclophosphamide;
intraplantar formalin: intraplantar injection of diluted formalin in hindpaw;
Acid-induced muscle pain: intramuscular injection of acidic saline (pH4) in
gastrocnemius; knee-joint arthritis: intraarticular injection of kaolin-caragenean
in knee; Sciatic nerve ligation or section: loose or tight ligation of sciatic nerve
or spinal roots, or sparing section of roots.
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basolateral nucleus which targets preferentially to the
CeM [4,7,11]. Additionally, lateral and basolateral pro-
jections to the CeA can be relayed in the intercalated
cell masses, providing an inhibitory interface in the
BLA-CeA pathway [4,12]. Moreover, the CeA also receives
less dense but direct projection from these thalamic and
cortical areas [17,18]. These largely polysynaptic efferents
thus allow the CeA to integrate a nociceptive information
which already acquired affective and cognitive significance
in cortical circuits.
A second pathway conveys to the CeA more direct
and raw nociceptive information. While spinal cord only
sparsely sends direct projection to the amygdala, spinal
nociceptive information is largely transmitted to the
CeA via the parabrachial nucleus (PB). This pontine in-
tegrative center is a major target for superficial layers of
the spinal cord, but also for deeper layers, for the tri-
geminal complex and for the nucleus of the solitary tract
[19,20]. The nociceptive aspect of these afferents was
clearly established by electrophysiology [20]. The PB
thus gathers nociceptive information from all cutaneous,
deep tissue and visceral territories. Three main ascend-
ing pathways are then originating from the PB, toward
the medial thalamus, the medial hypothalamus and the
central extended amygdala [20]. The parabrachio-
amygdaloid pathway is highly organized, with a specific
topography connecting various PB subdivisions to the
ones of the CeA and the BSTL [19,20]. Moreover, unitary
analysis of parabrachio-amygdaloid axonal branching
showed that the different components of the central ex-
tended amygdala are innervated by axonal collaterals from
a same PB neuronal population that never send projection
to the medial thalamus or the medial hypothalamus [21].
In vivo electrophysiological studies allowed character-
izing the response of CeA neurons to nociceptive stimu-
lations [6,19,20,22,23]. In anesthetized rats, cutaneous
(mechanical or thermal), deep tissue (articular and mus-
cular) and visceral nociceptive stimulations provoke
changes in the activity of a large majority of CeA neu-
rons (Table 1). Most of them, particularly in the CeLC,
are activated by nociceptive stimuli, either exclusively or
preferentially, while fewer neuronal inhibition can be ob-
served in the CeL. Few CeM neurons are responding to
nociceptive stimuli. This has led to define the CeLC as
the “nociceptive amygdala” [6] even though contribu-
tions from the CeL to nociceptive process cannot be
ruled out. The CeA neurons can encode the stimulus in-
tensity, as shown by sigmoid stimulus–response curves.
Receptor fields are particularly large, often bilateral and
can cover the whole body [20,22,23]. These neurons
often respond to both cutaneous and deep tissue stimu-
lation, whether mechanical or thermal. Together, these
data suggest that even though CeA neurons can detectnociceptive information, the stimulus–response shape of
this response as well as the wide receptor fields do not
allow the CeA to play a major role in the sensori-
discriminative aspect of pain. This brain region rather
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affective components of pain [5,6,19,20].
The recruitment of the CeA in visceral and inflamma-
tory pain has also been evidenced using the expression
of immediate early genes such as cfos (Table 1). For ex-
ample, intraperitoneal or esophageal acetic acid injection
[24,25], colorectal distension [42] or experimental cyst-
itis [28] induce cFos in the CeA and the BSTL. Interest-
ingly, this cellular recruitment in the CeA is not
observed after intradermal formalin injection in the
hindpaw. In this classical inflammatory pain model, cFos
recruitment rather appears in the basolateral nucleus of
the amygdala [24]. However, extracellular signal-regulated
kinase (ERK) phosphorylation is observed in the CeA after
intraplantar formalin [30] or in acid-induced muscle pain
[32]. Last, in visceral pain models but also in more persist-
ent pain models, such as knee intraarticular injection of
kaolin-carrageenan, or neuropathic models based on sci-
atic nerve ligation, major changes can be observed in the
CeA (Table 1), such as an increase in spontaneous and
evoked activity [33,34,37], an enhancement of synaptic
transmission at the PB-CeA and the BLA-CeA synapses
[35,38], an increase in the phosphorylation of NR1
glutamatergic subunit [36], an increased expression of
CRF, of group I metabotropic glutamatergic receptors
(mGluRs) and of corticosterone receptor [26,29,35,39,40]
and an increased cell proliferation [41].
Human brain imaging confirms a role of the amygdala
in pain processes [1]. However, the spatial resolution
only allows a crude discrimination of the various nuclei
of the amygdaloid complex. Globally, while older studies
failed to detect pain-related changes in the amygdala,
more recent studies revealed unilateral and bilateral acti-
vation or inhibition. These changes were observed after
nociceptive thermal laser stimulation [43,44] or colorec-
tal distention [45]. The amygdala response is usually cor-
related to the intensity of the nociceptive stimulus,
however the importance of attention and emotional fac-
tors has also been evidenced. Indeed, repeated thermal
nociceptive stimulations of increased intensity lead to an
activation of the amygdala that is correlated to the pain
perception [43]. However, when sub-threshold stimulus
is interpreted as painful by the subject, this situation
may activate the amygdala similar to a nociceptive pain-
ful stimulus reflecting a state of anxiety or the anticipa-
tion of a potentially aversive event. In another study
[44], the subjects were informed that they were about to
be expose to a cold painful stimulus lasting 1 minute, or
2 minutes. Functional imaging during the first minute of
stimulation revealed that the anticipation of longer
stimulus duration led to the deactivation of the amyg-
dala. This suggests that the impact of nociceptive infor-
mation on the amygdala depends on the context, and
not simply of the intrinsic properties of the stimulus.The CeA influences the nociceptive centers
The CeA receives and integrates nociceptive informa-
tion, but it also influences the main pain centers. The
CeA massively projects to other components of the cen-
tral extended amygdala, to the lateral hypothalamus and
to the brainstem [8]. Anatomical data indicate that the
intrinsic and the extrinsic projections to the central ex-
tended amygdala arise from distinct neuronal populations
[11]. Indeed, studies of unitary axonal reconstruction [46]
show that medium size spiny neurons of the CeLC and
the CeL mostly project to the BSTL and the dorsal
substantia innominata, while axons of CeM projection
neurons innervate the various brainstem structure
through collateral branches. Since the nociceptive inputs
from the PB preferentially target the CeLC and the CeL,
such organization suggest that nociceptive information
are integrated through an interneuron network intrinsic
to the CeA and to the central extended amygdala before
being delivered to output neurons influencing effector
centers of the brainstem. Some of these centers are part of
the nociceptive descending controls. Partially opioidergic
CeA outputs are for example innervating the PAG that is
a key element of descending controls of nociception
through its influence on the ventromedial reticular forma-
tion [47]. The PB is also part of descending controls and it
receives dense inputs from the CeA [8]. Beside these pro-
jections toward integrative centers, the CeA also directly
projects to the ventromedial reticular formation [48], the
dorsal reticular nucleus [49] and monoaminergic centers
such as the substantia nigra and the rostral ventral teg-
mental area (dopamine), the locus coeruleus (noradren-
aline) and the raphe nuclei (serotonin) [48,50-52]. These
structures are known to influence the nociceptive mes-
sage. Moreover, monoaminergic centers projecting to the
forebrain modulate striatal and cortical activities, poten-
tially influencing affective, emotional and motivational as-
pects of pain. Finally, within the central extended
amygdala, the dorsal substantia innominata that receives
strong inputs from the CeA – and particularly from the
CeLC – includes cholinergic neurons that innervate the
prefrontal and insular cortices [8,20].
Thus, the CeA has connections allowing the modula-
tion of both the sensory and the affective, emotional and
cognitive aspects of pain.
Amygdala, acute pain and analgesia
The potential role of the amygdala in the modulation of
pain has been suggested for a long time. It has been
clearly shown that the anti- and pro-nociceptive effects
are dependent on (1) the type of pain (acute, inflamma-
tory or chronic); (2) the measured parameters (threshold
or latency of reflex withdrawal, vocalizations, emotional
component); and (3) the emotional state of the subjects
(stress, anxiety, fear and expectation).
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of avoidance behavior or on the stimulus threshold, are
used to determine the analgesia or hyperalgesia [53].
These tests include for example the tail-flick (tail with-
drawal after a thermal stimulus), flinch test (paw or tail
withdrawal after electrical stimulation), hot-plate (paw
licking or jump after thermal stimulation) or Randall-
Selitto (paw withdrawal or vocalization after mechanical
stimulation). In these tests, the bilateral lesion or chem-
ical inactivation of the amygdala causes neither anti-
nociceptive nor pro-nociceptive effects in naïve animals
[54-56]. However, injections of neuropeptides such as
oxytocin, vasopressin, neurotensin, galanin, CRF or
CGRP [57-62], or of noradrenergic or cholinergic ago-
nists [63-66] into the CeA induce antinociceptive effects
(Table 2). In addition, the amygdala is involved in the
analgesic action of systemically administered morphine
and cannabinoids since the lesion or the inactivation of the
CeA strongly reduces the morphine- or cannabinoid-
induced analgesia as measured by the tail-flick test [56,67].
A recent study also showed that deleting the gene of brain-
derived neurotrophic factor (BDNF) in parabrachio-
amygdaloid neurons decreased the analgesic properties of
morphine in mechanical and thermal nociceptive modal-
ities [68]. Finally, the antinociceptive properties of intra-
CeA morphine or intra-CeA β-endorphin are dependent
upon opioidergic transmission in the amygdala-PAG path-
way [47].
These data therefore show that even if the CeA is not
directly involved in the modulation of basal nociceptive
thresholds in normal situations, it strongly influences
analgesia processes (Table 2).
Stressful situations (restraint or noise) and fear, espe-
cially the experimental model of fear conditioning, cause
analgesia as measured by the tail flick or the hot-plate
tests. Several studies demonstrated that bilateral lesion
or inactivation of the CeA diminishes or abolishes this
analgesic effect [55,69,70,80,92] (Table 2). In parallel,
clinical studies showed that stressful stimuli, either pain-
ful (electric shocks) or painless (unexpected noises), and
innocuous stimuli, previously associated with electric
shocks (fear conditioned), cause hypoalgesia in a finger
withdrawal test following thermal stimulation [93]. In
contrast, anxiety caused by electric shock induces hyper-
algesia [93]. Although the direct role of the amygdala in
these effects has not yet been shown in humans, the re-
sults in rodents are consistent with clearly defined func-
tions of the amygdala in emotional responses to
different aversive situations [2].
The amygdala thus can participate in adaptive pro-
cesses leading to alleviation of pain sensation but its role
is not limited to antinociception. While CeA lesion can
block the antinociception induced in the tail-flick test by
electrical shock pre-exposure, the affective hyperalgesia,measured by the latency to vocalize after the shock is
also reduced by the same CeA lesion [92]. Interestingly,
similar results are observed following lesion of the BSTL
[92]. Pharmacological manipulation of the CeA can also
increase visceromotor and/or somatomotor reflexes in
naïve animals, as shown by intra-CeA injection of ago-
nists to group I mGluRs [76,77]. Similarly, CGRP and
CRF administration in the CeA can induce mechanical
hypersensitivity [82,84], which is in contradiction with
older studies reporting antinociceptive effects of these
peptides [58,59] (see below). Finally, corticosterone im-
plants in the CeA sensitize the visceromotor reflexes to
colorectal and urinary bladder distension [87,88] and in-
creases mechanical sensitivity [89]. The amygdala is thus
likely to contribute to both analgesia and hyperalgesia.Amygdala, sustained pain, hyperalgesia and affective
component
Persistent pain, such as inflammatory or neuropathic
pain, has a different profile than acute pain. While ani-
mal studies often don’t address all the symptoms de-
scribed in humans, the models that are used can display
spontaneous nociceptive behaviors, hyperalgesia and/or
allodynia, aversion as well as the emotional conse-
quences of pain such as anxiety and depression [94].
The role of the CeA in sustained pain has been exam-
ined after intraplantar injection of formalin (somatic in-
flammatory pain), intraperitoneal injection of acetic acid
(visceral inflammatory pain), intraarticular injection of
kaolin and carrageenan (somatic inflammatory pain),
and ligation/compression of the sciatic nerve (neuro-
pathic pain) (Table 2). Generally, the manipulation of
CeA activity, either by activation or by inactivation, did
not modify the spontaneous nociceptive behaviors
[30,71,72]. However, persistent pain leads to increased
neuronal activity and synaptic transmission in the CeA
(Table 1) which may be involved in the induction and/or
maintenance of hypersensitivity observed in these
models [5,6,33,38]. Thus, inhibiting the extracellular
signal-regulated kinase (ERK) activation in the CeA de-
creases mechanical, but not thermal, hyperalgesia in for-
malin and arthritis models, while the direct activation of
ERK in the CeA is sufficient to produce mechanical
hyperalgesia in naïve animals [30,91]. In addition, intra-
CeA injections of mGluRs antagonist (groups I and III)
or of CGRP1 or CRF1 antagonists alleviate the increased
withdrawal reflexes as well as audible and ultrasonic vo-
calizations in monoarthritic animals [78,79,83,85,86]. In
neuropathic rats, activation of GABA-A receptors in the
CeA also diminishes mechanical hypersensitivity [74].
These data suggest that changes in the activity and
neurochemistry of the CeA contribute to the exacerba-
tion of nociceptive responses in persistent pain.
Table 2 Effects of CeA manipulation on pain-related outcomes in different pain models
Pain typea Pain related outcomeb Reference
Nociceptive behavior Affective/emotional
1. CeA lesion
Naïve - Reduced morphine-induced, stress-induced and conditioned hypoalgesia [55,56,69]
Formalin - Reduced morphine-induced and conditioned hypoalgesia - Decreased pain-induced CPA [70-73]
Acetic acid - Decreased pain-induced CPA [72]
2. Injection of muscimol
Neuropathy - Reduced mechanical hyperalgesia - Decreased escape/avoidance [74]
3. Injection of NMDA antagonist
Neuropathy - Decreased pain-induced CPA [75]
4. Injection of group I mGluRs ligands
Naïve - Agonist induced visceral and mechanical hypersensitivity [76,77]
- Antagonist reduced visceral sensitivity
Formalin - Antagonist reduced mechanical hypersensitivity [77]
Arthritis - Antagonist reduced mechanical hypersensitivity - Antagonist decreased vocalizations [78]
Neuropathy - Agonist increased, and antagonist
decreased, pain-induced CPA
[75]
5. Injection of group III mGluRs agonists
Naïve - Decreased mechanical sensitivity (mGluR7) - Decreased vocalizations and anxiety [79]
Arthritis - Increased mechanical sensitivity (mGluR8) - Increased vocalizations and anxiety [79]
6. Injection of cholinergic agonists
Naïve - Decreased thermal sensitivity, reduced jaw opening reflex - Decreased vocalizations [63,65,66]
7. Injection of noradrenergic α2 ligands
Naïve - Agonist induced mechanical and thermal hypoalgesia [64,80]
- Antagonist reduced stress-induced thermal hypoalgesia
Acetic acid - Agonist decreased pain-induced CPA [81]
8. Injection of noradrenergic β antagonists
Acetic acid - Decreased pain-induced CPA [81]
9. Injection of CGRP receptor ligands
Naïve - CGRP decreased mechanical and thermal reflexes [59]
Naïve - CGRP increased mechanical reflexes - CGRP increased vocalizations [82]
Arthritis - CGRP1 antagonist inhibited the enhanced reflex to mechanical stimulus - CGRP1 antagonist decreased vocalizations [83]
10. Injection of CRF receptor ligands
Naïve - CRF decreased mechanical and thermal sensitivity [58]
Naïve - CRF increases mechanical sensitivity - CRF increased vocalizations [84]
Arthritis - CRF1 antagonist reduced mechanical hypersensitivity - CRF1 antagonist decreased vocalizations
and anxiety
[85,86]
11. Injection of oxytocin, vasopressin, neurotensin, galanin
Naïve - Decreased mechanical and/or thermal sensitivity [57,60-62]
12. Injection of opioid receptors ligands
Naïve - Morphine and β-endorphin induced mechanical and thermal hypoalgesia - Morphine decreased vocalizations [47,66]
13. Corticosterone implants
Naïve - Sensitized visceromotor reflexes to colorectal and urinary bladder
distension and to somatic mechanical sensitivity
- Increased anxiety [87-90]
Veinante et al. Journal of Molecular Psychiatry 2013, 1:9 Page 7 of 14
http://www.jmolecularpsychiatry.com/content/1/1/9
Table 2 Effects of CeA manipulation on pain-related outcomes in different pain models (Continued)
14. BDNF gene deletion in the PB-CeA pathway
Naïve - Decreased morphine-induced mechanical and thermal hypoalgesia [68]
15. Intracellular effectors
Naïve - ERK activator induced mechanical hypersensitivity [30]
Formalin - ERK activation inhibitor decreased mechanical hypersensitivity [30,31]
Arthritis - ERK activation inhibitor and PKA inhibitor decreased mechanical
hypersensitivity
- ERK activation inhibitor and PKA inhibitor
decreased vocalizations
[91]
aPain type. naive nociceptive testing on naive animals; formalin: intraplantar injection of diluted formalin in hindpaw; acetic: intraperitoneal injection of acetic acid; arthritis:
intraarticular injection of kaolin-caragenean in knee; neuropathy: compression or ligation of sciatic nerve or spinal root.
bPain related outcome. thermal sensitivity: latency of withdrawal or escape in tail-flick, hot-plate or Heargraves tests; mechanical sensitivity: latency or threshold to
withdrawal in von Frey or Randall-Sellito tests; CPA: pain-induced conditioned place aversion; vocalizations: intensity/duration/threshold of vocalizations to electrical shock
(naive) or mechanical compression of knee (naive, arthritis); anxiety: anxiety-like behavior in elevated plus maze test.
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also be under the influence of the amygdala. The effects
of pharmacological manipulations of the CeA on vocali-
zations reported above (see also Table 1) are pertinent in
this context. Indeed, while audible vocalizations induced
by a nociceptive stimulus are believed to reflect
nocifensive responses, ultrasonic vocalizations would re-
flect an affective pain response [78,95]. A widely used
test to assess the affective/emotional component of pain,
is the pain-induced conditioned place aversion. This be-
havior is suppressed in the intraplantar formalin and in-
traperitoneal acetic acid models by bilateral lesions of
the CeA [72,73] or by injection of β-adrenoceptor antag-
onist [81]. Similarly, intra-CeA administration of a
GABA-A receptor agonist, a NMDA antagonist or a
group I mGluR antagonist reduces the place avoidance
behavior in neuropathic rats [74,75].
Finally, the CeA may be a part of the mechanism
linking sustained pain to anxiety and depression-like
states. It has been shown that the models of
monoarthritic pain or of sciatic nerve ligation induce
anxiety that is correlated with the activation of the CRF
system in the CeA. The expression of this neuropeptide,
which has a well established role in anxiety, is increased
in the CeA of neuropathic animals [39,40], while the
intra-CeA injection of CRF1 antagonist reduces anxious
behaviors produced by knee monoarthritis [85,86]. In
addition, the pronociceptive effects of corticosterone im-
plants in the CeA are accompanied by anxiety-like be-
haviors [90].
In humans, brain imaging studies [1] demonstrated
changes in the activity of the amygdala of patients
with irritable bowel syndrome [45], arthritis [96] or
mononeuropathy [97], suggesting that the amygdala
may be involved in the emotional aspects related to
these pathologies. Interestingly, a brain imaging study
showed the participation of an amygdala - anterior
cingulate cortex circuit in the higher subjective per-
ception of pain in healthy subjects experiencing sad-
ness [98]. Conversely, viewing pictures of a romanticpartner reduced self-reported pain, in association with
activation of the amygdala [99]. These data reinforce
the role of amygdala in emotional impact on pain.
In summary, the amygdala, particularly the CeA, may
have a mainly antinociceptive influence in acute/phasic
pain conditions associated with situations of stress or
fear, and a mainly pronociceptive influence in persistent/
tonic pain conditions which concerns the sensory as well
as the emotional and affective dimensions.
Potential mechanisms with several actors
Some information is available on the cellular and mo-
lecular mechanisms by which the amygdala can exert its
bidirectional effects on pain parameters. Projections from
the PB to the CeA give direct information about the per-
ceived nociceptive stimulation through glutamatergic and
peptidergic synapses [100-102], while the glutamatergic
projections from the BLA to the CeA can bring polymodal
information with an affective valence [5]. This latter input
can be turned into an inhibitory control through the inter-
calated cell masses, functionally placed between the BLA
and the CeA [4,12]. The influence of the CeA on its tar-
gets will depend on the confrontation of these inputs with
other afferent information. The internal network of the
CeA and of the central extended amygdala is based on
GABAergic inhibitory neurons [103], and the output of
this system can either be inhibitory or disinhibitory on
target structures [4,104,105]. Changes in the level of
pain perception seem to involve the projection of the
CeA to the centers of descending pain control, espe-
cially the PAG and the ventromedial reticular formation
[47], while the influence of the amygdala on the emo-
tional and affective dimensions of pain arises from a
larger network that involves indirect connections with
cortical regions such as the insular and the cingulate
cortex [5,20].
It is now clearly established that persistent pain causes
long-lasting changes in the activity of the CeA that could
account for its pronociceptive influence on sensory and
affective components of pain [5,6]. In arthritic, visceral
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ceptive neurons of the CeA exhibit increased membrane
excitability, leading to higher spontaneous activity, as well
as potentiation of synaptic transmission [27,33,35,37,38].
This synaptic plasticity, observed at both the PB-CeA and
the BLA-CeA synapses can potentiate nociceptive trans-
mission. Some specificity can be observed concerning pain-
related plasticity in the CeA. Indeed, in arthritis model, the
population of multireceptive neurons, responding to in-
nocuous stimuli but preferentially to nociceptive stimuli,
presents increased basal activity and increased responses to
mechanical but not thermal nociceptive stimuli. A second
neuronal population, normally insensitive to somatosensory
stimulation, develops responses to mechanical, but not
thermal nociceptive stimuli. In contrast, arthritis modifies
neither the basal activity nor the responses of the
nociceptive-specific neurons [33]. In addition, while the PB
and the BLA can synapse onto the same neurons, but on
different dendritic compartments [106], specific plastic
changes can occurs with different pain models. While arth-
ritic and neuropathic pain models potentiates both the PB-
CeA and the BLA-CeA synapses [33,38], a model of
visceral pain only potentiates the PB-CeA synapses [27].
An intriguing observation is that the right CeA ap-
pears largely more implicated in persistent pain than the
left CeA. Indeed, the activation of ERK after intraplantar
formalin is restricted to the right CeA, and the blockade
of ERK activation in the right CeA decreased mechanical
hyperalgesia at both hindpaws, irrespective to the side of
formalin injection [30,31]. In the arthritis model, the en-
hanced background activity and evoked responses are
observed only in the right CeA, as well as the decreased
activity following injection of a PKA inhibitor [34].
Finally, in neuropathic rats, spontaneous activity and
evoked responses increased in the left CeA 2 and 6 days
after sciatic nerve ligation, but declined afterward,
whereas these electrophysiological parameters increased
in the right CeA at 14 days post-ligation [37]. The differ-
ent implication of left and right CeA in pain processes
could partially account for the conflicting reports indi-
cating antinociceptive [58,59] and pronociceptive
[82,84] effects of CRF and CGRP injected into the CeA
of naive rats. The anatomical and functional basis of
this lateralization remains unclear, but it suggests a
strong relation between right amygdala and affective/
emotional component of persistent pain.
A number of neurochemical and molecular mecha-
nisms involved in the sensitization of the CeA have been
elucidated. They especially implicate the modification of
pre-and post-synaptic glutamatergic transmission, with
an impact on GABAergic transmission, along with
neuropeptidergic modulation [5,6] (Figure 3). Following
induction of experimental arthritis, the pre-synaptic ex-
pression of mGluR1 (group I) is increased, which in turnpotentiates the synaptic transmission [35,107]. This ef-
fect seems to involve a decreased inhibition, resulting in
disinhibition of CeLC neurons and of glutamatergic ter-
minals [108]. On the other hand, the activation of group
II and III pre-synaptic mGluRs diminishes synaptic
transmission [109-111]. At post-synaptic level, activation
of group I mGluR (mGluR5) in the CeLC increased the
excitatory response to nociceptive input in normal con-
dition but not in arthritic condition [108], possibly in-
volving PKA and ERK activation through reactive
oxygen species [112]. In the same inflammatory pain
model, NMDA ionotropic receptors are implicated in
post-synaptic a sensitization, via a PKA-dependant
mechanism [36,113], while a NMDA-independent syn-
aptic plasticity is induced in a neuropathic pain model
[38]. Last, neuropeptide receptors (CRF1, CGRP1) con-
tribute to this plasticity by favoring NMDA receptor
phosphorylation through the recruitment of PKA and
ERK kinases [82-84]. Together, these mechanisms lead
to both increased nociceptive transmission and neuron
sensitization in the CeA. The implication of CRF is here
important as it also plays a role in stress response and
anxiety. Moreover, while CGRP and CRF in CeA have a
pronociceptive influence in arthritis model, the same
neuropeptides can be acutely antinociceptive when dir-
ectly injected in the CeA of control animals [58,59]. This
dual action, which likely implies qualitative and quantita-
tive receptor changes, may also exist for other neuropep-
tides present in CeA, such as oxytocin or neurotensin.
Opioid system in the CeA may be important in these phe-
nomenons, but its contributions still remain elusive. The
three types of opioid receptors (mu, delta, kappa) are
expressed in the CeA, both pre- and post-synaptically, as
well as their endogenous ligands [15,16,114-116]. The opi-
oid system is a key actor in the CeA, due to the
enkephalin contribution to intrinsic communications
within the central extended amygdala and due to the con-
tribution of the other opioid peptides to extrinsic CeA
outputs [11]. The influence of the opioid system in the
amygdala on pain is supported by various data, including
the antinociceptive action of morphine in the CeA, the
synergy between the CeA and the PAG co-delivery of opi-
oid ligands [47] and the changes in CeA opioid receptor
binding in neuropathic mice [117]. However, the circuit
architecture underlying these actions, and the individual
role of each peptide and receptor, is not yet clearly de-
fined. For example, the mu-opioid receptors are pre-
synaptically present in the CeA, where they can inhibit
glutamate and GABA release from afferents [115,118], but
they also act post-synaptically to inhibit CeA interneurons
and projection neurons [116] (Figure 3). Thus, these re-
ceptors can either inhibit or activate each component of
the CeA. It is also not yet known how the opioid system in-
teracts with other neurotransmission systems within the
Figure 3 Molecular actors in nociceptive processing in the CeA during arthritic pain. The CeA received nociceptive inputs from
glutamatergic (Glu) neurons in the basolateral amygdala (BLA) and in the parabrachial nucleus (PB). GABAergic innervation originates from
intrinsic source (CeA and BSTL) and from the intercalated cell masses (ITC). Additional modulation is provided by monoaminergic (MA) and
cholinergic (ACh) afferents and by neuropeptides (Np), especially from CeA, BSTL and PB. These neuromediators act on excitatory (green) and
inhibitory (red) receptors at pre and post-synaptic levels. In the knee monoarthritis model [5], several mechanisms contribute to a enhanced
neurotransmission. At pre-synaptic level, mGluR1 receptors inhibit GABA release, while mGluR from groups II and III decrease glutamate release.
At post-synaptic level, mGluR5 receptors are involved in normal transmission in naive animals and NMDA and AMPA ionotropic receptors have
also an enhanced activity increasing neuronal sensitivity. CGRP, from PB, and CRF, possibly from the central extended amygdala itself, activate
their post-synaptic receptors, CGRP1 and CRF1, respectively. These receptors can activate the protein kinase A (PKA) and thus increase NMDA
phosphorylation. The extracellular regulated-signal kinase ERK also contributes to the sensitization of CeA neurons, possibly through a cascade
initiated by mGluR5 receptors. CRF can also decrease the activity of CeA neurons, via pre-synaptic CRF2 receptors increasing GABA release. This
leads to the inhibition of CeA neurons by activation of post-synaptic GABA A and GABA B receptors and by inhibition of glutamate release by
pre-synaptic GABA B receptors. Other neurotransmission system involving noradrenergic (NA, especially through pre-synaptic α2-receptors),
dopaminergic (DA), serotonergic (5-HT) and cholinergic (ACh) receptors can modulate CeA activity, as well as other neuropeptides, among them
opioids acting on pre- and post-synaptic mu receptors (MOR), and BDNF acting on TrkB receptors. Overall, these mechanisms lead to the
modulation of the intra-CeA circuitry, based on GABAergic interactions (in blue) and of the CeA output.
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act downstream to agents that promote antinociception
such as galanin or BDNF [60,68]. Finally, adrenoceptors
modulate pain processes in the CeA [64,80,81], especially
through α2 adrenoceptors located on PB-CeA pre-synaptic
elements which strongly regulate glutamate release [100].
Beyond the central amygdala
While we focused this review on the CeA, it is necessary
to remind the contribution of BSTL and BLA to pain
process.
The CeA belongs to the central extended amygdala; it
is largely interconnected with the BSTL and shares simi-
lar afferents, including polymodal and nociceptive inputs
from the BLA and the PB [8,21]. While there is no re-
port of an influence of the BSTL on nociceptive sensitiv-
ity, a few studies addressed its role in pain-induced
conditioned place aversion. Bilateral lesion of the BSTL
[119], as well as intra-BSTL injection of a β-adrenoceptor
antagonist [120,121], α2-adrenoceptor agonist [122] orCRF1 antagonist [123] decrease place aversion in the
intraplantar formalin and/or intraperitoneal acetic acid
models. Moreover, noradrenaline and CRF release in the
BSTL is enhanced in these pain models [120-122] and CRF
mRNA is upregulated in the BSTL of neuropathic rats
[40]. These data suggest that the BSTL can be involved in
affective/emotional component of pain, maybe in a
complementary manner with the CeA, especially in
view of BSTL implication in anxiety [3].
The BLA, beyond its role as a mere input provider to the
CeA and BSTL, also appears as an important actor in pain
processes. Some observations suggest that the BLA and
the CeA can have a parallel role in nocifensive responses.
Stress- and fear-induced analgesia are reduced by intra-
BLA infusion of cannabinoid CB1 receptors antagonists, of
muscimol or of diazepam [124-127]; mu opioid agonist, in-
cluding morphine, injected in the BLA decreases vocaliza-
tions to tail shocks [128] and thermal nociceptive
sensitivity [129,130]. Sustained pain also impacts the BLA
as intraplantar formalin induces c-fos mRNA [24], arthritis
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tumor necrosis factor α (TNF-α) [131] and neuropathy in-
creases cell proliferation in the BLA [41]. A functional
plasticity of BLA neurons is also observed in arthritis
model, characterized by an increased in spontaneous and
evoked activity and enhanced synaptic transmission. This
pain-induced plasticity can be reversed by CRF1 antagon-
ism [132].
The affective component of pain can also be modu-
lated by the BLA. The formalin-induced conditioned
place aversion is reduced by lesion of the BLA [72], as it
is the case for the CeA and the BSTL, but also by BLA
injection of NMDA antagonist or of morphine [133]. In
addition, neutralizing BLA TNF-α with Infliximab anti-
bodies reduced anxiety-like behaviors associated to arth-
ritis [131]. Finally, CRF1 antagonism in BLA of arthritic
rats decreased mechanical hypersensitivity, but also
pain-related vocalizations and anxiety [132].
These influences of BLA on sensory and affective/
emotional aspects of pain can, at least in part, involve its
outputs to the CeA and/or BSTL. However, the BLA also
appears to be implicated in pain-related cognitive
impairment. Indeed, in arthritic rats, blockade of pain-
induced plasticity in the BLA with CRF1 antagonism
reversed the deficit in decision making evaluated in a
gambling task. This deficit has been shown to be
dependent upon a deactivation of the medial prefrontal
cortex driven by the hyperactivity in the BLA. Import-
antly, this mechanism appears independent of the CeA
[132]. Thus, the connections of the BLA with the cere-
bral cortex, especially prefrontal, cingulate and insular
cortices, could allow the amygdala to influence both the
affective/emotional and the cognitive aspects of pain. In
addition, the dense BLA input to the ventral striatum
[9,10] could also participates in pain-induced changes in
motivation and goal-directed behaviors.
Conclusions
The data from the literature show that the amygdala, and
in particular the CeA, contributes to pain processes. Its
anatomical and functional relations with pain ascending
systems, with pain facilitating or inhibitory descending
systems, and with affective and cognitive centers are pla-
cing the CeA in a critical position within the pain matrix.
Acute pain reactions only require CeA if they occur in
specific emotional or adaptive contexts. On the other side,
persistent and chronic pains alter CeA activity, which in-
fluences the pain experience and the related emotional,
affective and motivational states. Reciprocally, these states
can modify the amygdala processing of information and
its impact on pain.
The amygdala has been mostly considered for its roles
in emotion, especially in fear [2,4]. While most studies
focused on the BLA, recent researches on the fear circuitdisclosed a part of the CeA microcircuitry involved in
fear conditioning [104,105]. It is very likely that a similar,
if not the same, circuit underlies CeA functions in pain.
Indeed, a recent study showed for the first time that the
“nociceptive” amygdala (CeLC) undergoes synaptic plas-
ticity at the PB-CeA and the BLA-CeA synapses during
fear conditioning [134]. This result emphasizes the need
to consider the strong relation between pain and emo-
tion. The contribution to the pain matrix of the CeA, of
other components of the amygdala and of the central ex-
tended amygdala, should foster researches in the context
of chronic pain and the associated anxio-depressive
disorders.
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